Cyclophosphamide
Transplant-Related Disorder
Actinium PharmaceuticalsSmall moleculePhase 2/3Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Transplant-Related Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Actinium Pharmaceuticals | Phase 2/3 | B |
MONOCLONAL ANTIBODY BC8 Actinium Pharmaceuticals | Phase 2/3 | B |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →